查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
精神抗生素市场 - 2018-2028 年全球行业规模、份额、趋势、竞争、机会和预测，按精神药物、形式、应用、地区和竞争细分
市场调查报告书
商品编码
1321048

精神抗生素市场 - 2018-2028 年全球行业规模、份额、趋势、竞争、机会和预测，按精神药物、形式、应用、地区和竞争细分

Psychobiotics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent, By Form, By Application, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 110 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计全球精神生物市场将在 2024-2028 年预测期内实现非凡增长。市场的增长可归因于人们对压力、焦虑和睡眠障碍等心理健康问题的日益关注。根据 2019 年全球疾病、伤害和危险因素负担研究 (GBD)，焦虑症和抑郁症是两种最使人丧失能力的精神疾病，位列 2019 年全球疾病负担的前 25 位主要原因。董事会，男女皆宜，遍布全球。也许更重要的是，儘管有强有力的证据表明治疗可以减轻其影响，但尚未观察到这两种疾病的全球患病率或负担有所下降。此外，COVID-19 的突然爆发以及 2020-2021 年全球不同国家为遏制该病毒而实施的封锁增加了人们的心理健康问题。

对益生菌治疗焦虑和抑郁的需求不断增加

通过影响微生物-肠-脑轴，益生菌可以对情绪和宿主健康产生影响。压力、焦虑和抑郁都涉及情绪的逐渐淡化。焦虑是对压力的一种反应，但如果它持续存在并受到不当治疗，它可能会发展成更严重的精神疾病，例如抑郁症。压力通常来自各种对身体或情感要求较高的事件，以及对紧急情况的短暂反应。许多研究发现人们的焦虑和抑郁之间存在微妙的联繫。根据澳大利亚的数据，28% 具有临床显着焦虑的患者还患有抑郁症，大约 57% 的抑郁症患者还患有焦虑症。

根据一些研究，已证明肠道菌群在情绪调节中发挥着积极作用，并且益生菌具有广泛的用途。一些研究表明，患有重度抑郁症的受试者中变形菌门、拟桿菌门和放线菌门的水平增加，而厚壁菌门的数量显着减少。益生菌对中枢神经系统活动和行为有多种影响。首先，一些局部细菌可以诱导宿主细胞产生神经递质，包括血清素、多巴胺和 GABA。此外，微生物可以改变大脑神经递质受体的表达。通过引起抗炎细胞因子的增加和促炎细胞因子的减少（一种与控制肠道通透性相关的模式），益生菌还有助于减少全身炎症。

鑑于益生菌有益于精神疾病，研究益生菌在治疗压力、焦虑和抑郁等精神健康疾病中的应用的临床试验数量也在激增。因此，这将进一步有助于未来几年全球精神生物市场的扩张。

焦虑和抑郁病例激增

最常影响人们的两种精神疾病是抑郁症和焦虑症。抑郁症是情绪障碍的主要类型之一，其特征是情绪不佳和兴趣丧失，常常伴有内疚、绝望、食慾不振和失眠。焦虑是一种紧张、担忧和恐惧的感觉，以及没有明确客观原因的心悸、颤抖以及消化、呼吸和循环系统问题等身体变化。根据世界卫生组织 (WHO) 的估计，2015 年，焦虑症的患病率预计为 3.6%，抑郁症的患病率预计将达到 4.4%。

COVID-19 大流行还对世界各地患者的心理健康产生了最严重的影响。根据《柳叶刀》发表的一项研究，全球男女焦虑症的发病率均增加了 25.6%。抑郁症患病率增加了 27.6%。这两种疾病的患病率在女性中明显高于男性。女性抑郁症患病率增加了 29.8%，而女性焦虑症患病率增加了 27.9%，男性增加了 21.7%。

消费者意识不断提高

预计该市场的增长也将受到精神生物改善身体一般过程（包括消费者消化）的能力的推动。由于精神生物学能够满足胃肠道和免疫系统等特定消费者需求，以及产品开发的最新进展，预计需求也会增加。

凯爱瑞集团2019 年对2,100 名具有健康意识的美国人进行的一项全球民意调查显示，62% 的受访者知道什么是益生菌，32% 的受访者在过去六个月内使用过益生菌。 79% 了解益生菌的美国人表示，改善消化系统健康是他们在产品中寻求的最重要的健康益处。

此外，製造商正在投入大量精力开发具有新形式、饮食要求和包装的创新精神生物相关产品。由于製造商推出纯素和无麸质精神药物产品，具有健康意识和纯素食的消费者对精神药物的需求不断增加。因此，越来越多的人在生活中采用益生菌来改善和健康的生活方式。这可能会在预测的几年内扩大精神生物产业。

可用的定制：

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

  • 品牌意识
  • 首选购买方式
  • 导致精神疾病的主要因素
  • 对精神抗生素消费的意愿
  • 消费后常见的心理影响

第 5 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究应用分類的管道细分
  • 按地区分類的管道明细
  • 临床试验热图

第 6 章：专利分析

第 7 章：全球精神抗生素市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市场份额及预测
    • 精神药物（链球菌、双歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液体/流体、片剂、其他）
    • 按应用（压力管理、情绪健康和情绪提升、抑郁、焦虑、睡眠问题等）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 通过精神药物
    • 按形式
    • 按申请
    • 按地区
  • 定价分析

第 8 章：北美精神抗生素市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市场份额及预测
    • 精神药物（链球菌、双歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液体/流体、片剂、其他）
    • 按应用（压力管理、情绪健康和情绪提升、抑郁、焦虑、睡眠问题等）
    • 按国家/地区
  • 定价分析
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：欧洲精神抗生素市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市场份额及预测
    • 精神药物（链球菌、双歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液体/流体、片剂、其他）
    • 按应用（压力管理、情绪健康和情绪提升、抑郁、焦虑、睡眠问题等）
    • 按国家/地区
  • 定价分析
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙
    • 瑞典
    • 波兰
    • 斯洛伐克

第 10 章：亚太地区精神抗生素市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市场份额及预测
    • 精神药物（链球菌、双歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液体/流体、片剂、其他）
    • 按应用（压力管理、情绪健康和情绪提升、抑郁、焦虑、睡眠问题等）
    • 按国家/地区
  • 定价分析
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳大利亚
    • 台湾
    • 马来西亚
    • 新加坡

第 11 章：南美洲精神抗生素市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市场份额及预测
    • 精神药物（链球菌、双歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液体/流体、片剂、其他）
    • 按应用（压力管理、情绪健康和情绪提升、抑郁、焦虑、睡眠问题等）
    • 按国家/地区
  • 定价分析
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 12 章：中东和非洲精神抗生素市场展望

  • 市场规模及预测
    • 按价值和数量
  • 市场份额及预测
    • 精神药物（链球菌、双歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液体/流体、片剂、其他）
    • 按应用（压力管理、情绪健康和情绪提升、抑郁、焦虑、睡眠问题等）
    • 按国家/地区
  • 定价分析
  • MEA：国家分析
    • 南非精神生物
    • 沙特阿拉伯精神生物
    • 阿联酋精神生物

第 13 章：市场动态

  • 司机
    • 增加益生菌的使用来治疗焦虑和抑郁
    • 焦虑和抑郁患者激增
    • 青少年自我诊断、自我治疗倾向
  • 挑战
    • 对身体健康的不利影响
    • 内分泌和代谢副作用
    • 发展中国家和欠发达国家不可用

第 14 章：市场趋势与发展

  • 临床试验数量不断增加
  • 竞争加剧和即将到来的创新
  • 併购

第15章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（据报导）
  • 最近的发展
  • SWOT分析
    • InnovixLabs
    • Bened Biomedical Co., Ltd
    • Nutrimmun GmbH
    • Kerry Group Plc.
    • Sabinsa Corporation
    • Lallemand Health Solutions Inc.
    • DuPont de Nemours, Inc.
    • Uplift Food Pty Ltd.
    • Nature's Bounty Co. Ltd.
    • BioGaia Group
    • The Life Extension Foundation
    • Lifted Naturals

第 16 章：战略建议

简介目录
Product Code: 7678

Global Psychobiotics market is projected to accomplish extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, and sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and the imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.

A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.

Increasing Demand for Probiotics to Treat Anxiety and Depression

By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.

Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines-a pattern connected to the control of intestinal permeability-probiotics also assist in reducing systemic inflammation.

Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.

Surge in Cases of Anxiety and Depression

The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.

The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.

Rising Consumer Awareness

The market's growth is also anticipated to be fueled by the psychobiotic capacity to improve the body's general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.

According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.

In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.

Market Segmentation

Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.

Company Profiles

Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

Report Scope

In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent:

  • Streptococcus
  • Bifidobacterium
  • Lactobacillus
  • Clostridium
  • Others

Psychobiotics Market, By Form:

  • Powder
  • Liquid/Fluid
  • Tablets
  • Others

Psychobiotics Market, By Application:

  • Stress Management
  • Mood Health & Mood Upliftment
  • Depression
  • Anxiety
  • Sleep Problems
  • Others

Psychobiotics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
    • Sweden
    • Poland
    • Slovakia
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Taiwan
    • Malaysia
    • Singapore
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Brand Awareness
  • 4.2. Preferred Mode of Purchase
  • 4.3. Major Factors Contributing to Mental Illness
  • 4.4. Willingness towards Psychobiotics Consumption
  • 4.5. Commonly Observed Psychological Effect Post Consumption

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patents Analysis

7. Global Psychobiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Product Market Map
    • 7.3.1. By Psychotropic Agent
    • 7.3.2. By Form
    • 7.3.3. By Application
    • 7.3.4. By Region
  • 7.4. Pricing Analysis

8. North America Psychobiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 8.2.4. By Country
  • 8.3. Pricing Analysis
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Psychobiotics Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value & Volume
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Psychotropic Agent
        • 8.4.1.2.2. By Form
        • 8.4.1.2.3. By Application
      • 8.4.1.3. Pricing Analysis
    • 8.4.2. Mexico Psychobiotics Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value & Volume
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Psychotropic Agent
        • 8.4.2.2.2. By Form
        • 8.4.2.2.3. By Application
      • 8.4.2.3. Pricing Analysis
    • 8.4.3. Canada Psychobiotics Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value & Volume
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Psychotropic Agent
        • 8.4.3.2.2. By Form
        • 8.4.3.2.3. By Application
      • 8.4.3.3. Pricing Analysis

9. Europe Psychobiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 9.2.4. By Country
  • 9.3. Pricing Analysis
  • 9.4. Europe: Country Analysis
    • 9.4.1. France Psychobiotics Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value & Volume
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Psychotropic Agent
        • 9.4.1.2.2. By Form
        • 9.4.1.2.3. By Application
      • 9.4.1.3. Pricing Analysis
    • 9.4.2. Germany Psychobiotics Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value & Volume
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Psychotropic Agent
        • 9.4.2.2.2. By Form
        • 9.4.2.2.3. By Application
      • 9.4.2.3. Pricing Analysis
    • 9.4.3. United Kingdom Psychobiotics Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value & Volume
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Psychotropic Agent
        • 9.4.3.2.2. By Form
        • 9.4.3.2.3. By Application
      • 9.4.3.3. Pricing Analysis
    • 9.4.4. Italy Psychobiotics Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value & Volume
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Psychotropic Agent
        • 9.4.4.2.2. By Form
        • 9.4.4.2.3. By Application
      • 9.4.4.3. Pricing Analysis
    • 9.4.5. Spain Psychobiotics Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value & Volume
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Psychotropic Agent
        • 9.4.5.2.2. By Form
        • 9.4.5.2.3. By Application
      • 9.4.5.3. Pricing Analysis
    • 9.4.6. Sweden Psychobiotics Market Outlook
      • 9.4.6.1. Market Size & Forecast
        • 9.4.6.1.1. By Value & Volume
      • 9.4.6.2. Market Share & Forecast
        • 9.4.6.2.1. By Psychotropic Agent
        • 9.4.6.2.2. By Form
        • 9.4.6.2.3. By Application
      • 9.4.6.3. Pricing Analysis
    • 9.4.7. Poland Psychobiotics Market Outlook
      • 9.4.7.1. Market Size & Forecast
        • 9.4.7.1.1. By Value & Volume
      • 9.4.7.2. Market Share & Forecast
        • 9.4.7.2.1. By Psychotropic Agent
        • 9.4.7.2.2. By Form
        • 9.4.7.2.3. By Application
      • 9.4.7.3. Pricing Analysis
    • 9.4.8. Slovakia Psychobiotics Market Outlook
      • 9.4.8.1. Market Size & Forecast
        • 9.4.8.1.1. By Value & Volume
      • 9.4.8.2. Market Share & Forecast
        • 9.4.8.2.1. By Psychotropic Agent
        • 9.4.8.2.2. By Form
        • 9.4.8.2.3. By Application
      • 9.4.8.3. Pricing Analysis

10. Asia-Pacific Psychobiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 10.2.4. By Country
  • 10.3. Pricing Analysis
  • 10.4. Asia-Pacific: Country Analysis
    • 10.4.1. China Psychobiotics Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Psychotropic Agent
        • 10.4.1.2.2. By Form
        • 10.4.1.2.3. By Application
      • 10.4.1.3. Pricing Analysis
    • 10.4.2. India Psychobiotics Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Psychotropic Agent
        • 10.4.2.2.2. By Form
        • 10.4.2.2.3. By Application
      • 10.4.2.3. Pricing Analysis
    • 10.4.3. South Korea Psychobiotics Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Psychotropic Agent
        • 10.4.3.2.2. By Form
        • 10.4.3.2.3. By Application
      • 10.4.3.3. Pricing Analysis
    • 10.4.4. Japan Psychobiotics Market Outlook
      • 10.4.4.1. Market Size & Forecast
        • 10.4.4.1.1. By Value & Volume
      • 10.4.4.2. Market Share & Forecast
        • 10.4.4.2.1. By Psychotropic Agent
        • 10.4.4.2.2. By Form
        • 10.4.4.2.3. By Application
      • 10.4.4.3. Pricing Analysis
    • 10.4.5. Australia Psychobiotics Market Outlook
      • 10.4.5.1. Market Size & Forecast
        • 10.4.5.1.1. By Value & Volume
      • 10.4.5.2. Market Share & Forecast
        • 10.4.5.2.1. By Psychotropic Agent
        • 10.4.5.2.2. By Form
        • 10.4.5.2.3. By Application
      • 10.4.5.3. Pricing Analysis
    • 10.4.6. Taiwan Psychobiotics Market Outlook
      • 10.4.6.1. Market Size & Forecast
        • 10.4.6.1.1. By Value & Volume
      • 10.4.6.2. Market Share & Forecast
        • 10.4.6.2.1. By Psychotropic Agent
        • 10.4.6.2.2. By Form
        • 10.4.6.2.3. By Application
      • 10.4.6.3. Pricing Analysis
    • 10.4.7. Malaysia Psychobiotics Market Outlook
      • 10.4.7.1. Market Size & Forecast
        • 10.4.7.1.1. By Value & Volume
      • 10.4.7.2. Market Share & Forecast
        • 10.4.7.2.1. By Psychotropic Agent
        • 10.4.7.2.2. By Form
        • 10.4.7.2.3. By Application
      • 10.4.7.3. Pricing Analysis
    • 10.4.8. Singapore Psychobiotics Market Outlook
      • 10.4.8.1. Market Size & Forecast
        • 10.4.8.1.1. By Value & Volume
      • 10.4.8.2. Market Share & Forecast
        • 10.4.8.2.1. By Psychotropic Agent
        • 10.4.8.2.2. By Form
        • 10.4.8.2.3. By Application
      • 10.4.8.3. Pricing Analysis

11. South America Psychobiotics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 11.2.4. By Country
  • 11.3. Pricing Analysis
  • 11.4. South America: Country Analysis
    • 11.4.1. Brazil Psychobiotics Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Psychotropic Agent
        • 11.4.1.2.2. By Form
        • 11.4.1.2.3. By Application
      • 11.4.1.3. Pricing Analysis
    • 11.4.2. Argentina Psychobiotics Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Psychotropic Agent
        • 11.4.2.2.2. By Form
        • 11.4.2.2.3. By Application
      • 11.4.2.3. Pricing Analysis
    • 11.4.3. Colombia Psychobiotics Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Psychotropic Agent
        • 11.4.3.2.2. By Form
        • 11.4.3.2.3. By Application
      • 11.4.3.3. Pricing Analysis

12. Middle East and Africa Psychobiotics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 12.2.4. By Country
  • 12.3. Pricing Analysis
  • 12.4. MEA: Country Analysis
    • 12.4.1. South Africa Psychobiotics Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Psychotropic Agent
        • 12.4.1.2.2. By Form
        • 12.4.1.2.3. By Application
      • 12.4.1.3. Pricing Analysis
    • 12.4.2. Saudi Arabia Psychobiotics Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Psychotropic Agent
        • 12.4.2.2.2. By Form
        • 12.4.2.2.3. By Application
      • 12.4.2.3. Pricing Analysis
    • 12.4.3. UAE Psychobiotics Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Psychotropic Agent
        • 12.4.3.2.2. By Form
        • 12.4.3.2.3. By Application
      • 12.4.3.3. Pricing Analysis

13. Market Dynamics

  • 13.1. Drivers
    • 13.1.1. Increased Use of Probiotics for Anxiety and Depression
    • 13.1.2. Surge in Subjects with Anxiety and Depression
    • 13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
  • 13.2. Challenges
    • 13.2.1. Detrimental Effects on Physical Health
    • 13.2.2. Endocrine and Metabolic Side Effects
    • 13.2.3. Unavailability in Developing Countries and Under-Developed Countries

14. Market Trends & Developments

  • 14.1. Increasing Number of Clinical Trials
  • 14.2. Increased Competition and Upcoming Innovations
  • 14.3. Mergers & Acquisitions

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As Reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. InnovixLabs
    • 15.6.2. Bened Biomedical Co., Ltd
    • 15.6.3. Nutrimmun GmbH
    • 15.6.4. Kerry Group Plc.
    • 15.6.5. Sabinsa Corporation
    • 15.6.6. Lallemand Health Solutions Inc.
    • 15.6.7. DuPont de Nemours, Inc.
    • 15.6.8. Uplift Food Pty Ltd.
    • 15.6.9. Nature's Bounty Co. Ltd.
    • 15.6.10. BioGaia Group
    • 15.6.11. The Life Extension Foundation
    • 15.6.12. Lifted Naturals

16. Strategic Recommendations